James D. Joseph

ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment

Nicola J. Clegg, John Wongvipat, James D. Joseph et al. · Cancer Research · 2012 · 660 citations

Medicine, Oncology, Pharmacology +17

A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509

James D. Joseph, Nhin Lu, Jing Qian et al. · Cancer Discovery · 2013 · 581 citations · Full text

Medicine, Oncology, Pharmacology +17

Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts

Andiliy Lai, Mehmet Kahraman, Steven P. Govek et al. · Journal of Medicinal Chemistry · 2015 · 247 citations · Full text

Medicine, Oncology, Pharmacology +13

The Homeodomain Protein HOXB13 Regulates the Cellular Response to Androgens

John D. Norris, Ching‐yi Chang, Bryan M. Wittmann et al. · Molecular Cell · 2009 · 220 citations · Full text

Life Sciences, Genetics, Molecular Biology +14

WNT11 Expression Is Induced by Estrogen-Related Receptor α and β-Catenin and Acts in an Autocrine Manner to Increase Cancer Cell Migration

Mary A. Dwyer, James D. Joseph, Hilary E. Wade et al. · Cancer Research · 2010 · 137 citations · Full text

Life Sciences, Molecular Biology, Oncology +17